The Fine Chemicals Market - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Fine Chemicals Market
Pharmaceutical Technology Europe interviews Andreas Stolle, head of business line pharma at Saltigo GmbH, about the state of the fine chemicals market and how demand looks set to change in the coming years.


Pharmaceutical Technology Europe
Volume 23, Issue 9

In looking at the outsourced relationship itself, do you think there is increased interest by pharmaceutical companies to work with fewer suppliers and form preferred provider relationships?

There is a clear trend to work with fewer preferred suppliers. Also, pharma companies are starting to focus more on their core business and seek increasing amounts of input and solutions from their suppliers. Thus, they may work with an external expert to access what specialised activities they can best provide best, as these activities may not be in a field of expertise for the pharmaceutical company.

As closer relationships with preferred suppliers evolve, more frequent and open communication is a necessity. A Joint effort, with common goals and shared risk and reward, is today’s widely accepted business model. Some pharmaceutical companies have even created “true external manufacturing departments” where they manage the suppliers as if they are part of the internal organisation.

Looking ahead five years for now, how do you see the market for contract pharmaceutical development and manufacturing evolving?

Going down the line of consolidation, future pharmaceutical fine chemicals companies may look different to those of today:

  • A critical size may be required to stay competitive, optimise and balance their portfolio, and benefit from other synergies.
  • A more global presence will be essential (i.e., marketing and production assets in different parts of the world to balance currency risks whilst also having more flexibility to stay close to local developing markets).
  • Diversification may also be revisited; for example, pharmaceutical fine chemical companies could expand into agro fine chemicals or other business segments. These pharmaceutical fine chemicals may become part of a larger conglomerate or add a 2nd or 3rd market offering to their portfolio that has different business cycles.

All of these changes need to be made whilst maintaining a very flexible, lean, creative and responsive organisation. 


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here